Portopulmonary hypertension: Challenges in diagnosis and management

Therapeutic Advances in Gastroenterology

Volumn 2, Issue 5, 2009, Pages 281-286

  Troy, Patrick J ^a   Waxman, Aaron B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Liver disease; Portal hypertension; Portopulmonary hypertension; Pulmonary hypertension; Vasodilators

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; PROSTACYCLIN; SILDENAFIL; VASODILATOR AGENT;

AGE DISTRIBUTION; AUTOIMMUNE DISEASE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; HUMAN; LIVER DISEASE; MORALITY; MORBIDITY; PATHOGENESIS; PATHOPHYSIOLOGY; PORTOPULMONARY HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SEX DIFFERENCE; THROMBOSIS;

EID: 77953464797     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X09338431     Document Type: Review

References (44)

1. Alam, I., Bass, N.M., Bacchetti, P., Gee, L. and Rockey, D.C. ( 2000) Hepatic tissue endothelin-1 levels in chronic liver disease correlate with disease severity and ascites. Am J Gastroenterol 95: 199-203.
2. Austin, M.J., Mcdougall, N.I., Wendon, J.A., Sizer, E., Knisely, A.S., Rela, M. et al. (2008) Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 14: 287-291.
3. Badesch, D.B., Abman, S.H., Ahearn, G.S., Barst, R.J., McCrory, D.C., Simonneau, G. et al. (2004) Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126: 35S-62S.
4. Barst, R.J., Rubin, L.J., Long, W.A., McGoon, M.D., Rich, S., Badesch, D.B. et al. (1996) A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302.
5. Barst, R.J., Rubin, L.J., McGoon, M.D., Caldwell, E.J., Long, W.A. and Levy, P.S. ( 1994) Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121: 409-415.
6. Benjaminov, F.S., Prentice, M., Sniderman, K.W., Siu, S., Liu, P. and Wong, F. ( 2003) Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52: 1355-1362.
7. Berkels, R., Klotz, T., Sticht, G., Englemann, U. and Klaus, W. ( 2001) Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. J Cardiovasc Pharmacol 37: 413-421.
8. Castro, M., Krowka, M.J., Schroeder, D.R., Beck, K.C., Plevak, D.J., Rettke, S.R. et al. (1996) Frequency and clinical implications of increased pulmonary artery pressures in liver transplant patients. Mayo Clin Proc 71: 543-551.
9. Cotton, C.L., Gandhi, S., Vaitkus, P.T., Massad, M.G., Benedetti, E., Mrtek, R.G. et al. (2002) Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. Liver Transpl 8: 1051-1054.
10. Egermayer, P., Town, G.I. and Peacock, A.J. ( 1999) Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 54: 161-168.
11. Findlay, J.Y., Plevak, D.J., Krowka, M.J., Sack, E.M. and Porayko, M.K. ( 1999) Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl Surg 5: 362-365.
12. Fix, O.K., Bass, N.M., de Marco, T. and Merriman, R.B. ( 2007) Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 13: 875-885.
13. Gough, M.S. and White, R.J. (2009) Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension. Liver Transpl 15: 30-36.
14. Hadengue, A., Benhayoun, M.K., Lebrec, D. and Benhamou, J.P. ( 1991) Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 100: 520-528.
15. Halank, M., Marx, C., Miehlke, S. and Hoeffken, G. ( 2004) Use of aerosolized inhaled iloprost in the treatment of portopulmonary hypertension. J Gastroenterol 39: 1222-1223.
16. Hemnes, A.R. and Robbins, I.M. (2009) Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation. Liver Transpl 15: 15-19.
17. Hirata, Y., Emori, T., Eguchi, S., Kanno, K., Imai, T., Ohta, K. et al. (1993) Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 91: 1367-1373.
18. Hoeper, M.M., Krowka, M.J. and Strassburg, C.P. ( 2004) Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 363: 1461-1468.
19. Hoeper, M.M., Seyfarth, H.J., Hoeffken, G., Wirtz, H., Spiekerkoetter, E., Pletz, M.W. et al. (2007) Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 30: 1096-1102.
20. Iwakiri, Y. and Groszmann, R.J. ( 2006) The hyper-dynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43: S121-S131
21. Kawut, S.M., Krowka, M.J., Trotter, J.F., Roberts, K.E., Benza, R.L., Badesch, D.B. et al. (2008) Clinical risk factors for portopulmonary hypertension. Hepatology 48: 196-203.
22. Kawut, S.M., Taichman, D.B., Ahya, V.N., Kaplan, S., Archer-Chicko, C.L., Kimmel, S.E. et al. (2005) Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 11: 1107-1111.
23. Kim, W.R., Krowka, M.J., Plevak, D.J., Lee, J., Rettke, S.R., Frantz, R.P. et al. (2000) Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 6: 453-458.
24. Krowka, M.J., Frantz, R.P., McGoon, M.D., Severson, C., Plevak, D.J. and Wiesner, R.H. ( 1999) Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 30: 641-648.
25. Krowka, M.J., Plevak, D.J., Findlay, J.Y., Rosen, C.B., Wiesner, R.H. and Krom, R.A. ( 2000) Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 6: 443-450.
26. Krowka, M.J., Swanson, K.L., Frantz, R.P., Mcgoon, M.D. and Wiesner, R.H. ( 2006) Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 44: 1502-1510.
27. Kuo, P.C., Johnson, L.B., Plotkin, J.S., Howell, C.D., Bartlett, S.T. and Rubin, L.J. ( 1997) Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63: 604-606.
28. Le Pavec, J., Souza, R., Herve, P., Lebrec, D., Savale, L., Tcherakian, C. et al. (2008) Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 178: 637-643.
29. Lebrec, D., Capron, J.P., Dhumeaux, D. and Benhamou, J.P. ( 1979) Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis 120: 849-856.
30. Makisalo, H., Koivusalo, A., Vakkuri, A. and Hockerstedt, K. ( 2004) Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 10: 945-950.
31. Mandell, M.S. and Groves, B.M. ( 1996) Pulmonary hypertension in chronic liver disease. Clin Chest Med 17: 17-33.
32. Mantz Jr, F.A. and Craige, E. ( 1951) Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol 52: 91-97.
33. Masaki, T. ( 1998) The discovery of endothelins. Cardiovasc Res 39: 530-533.
34. McGoon, M.D., Frost, A.E., Oudiz, R.J., Badesch, D.B., Galie, N., Olschewski, H. et al. (2009) Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 135: 122-129.
35. McLaughlin, V.V., Genthner, D.E., Panella, M.M., Hess, D.M. and Rich, S. ( 1999) Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130: 740-743.
36. Minder, S., Fischler, M., Muellhaupt, B., Zalunardo, M.P., Jenni, R., Clavien, P.A. et al. (2004) Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 24: 703-707.
37. Panos, R.J. and Baker, S.K. ( 1996) Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 17: 151-169.
38. Reichenberger, F., Voswinckel, R., Steveling, E., Enke, B., Kreckel, A., Olschewski, H. et al. (2006) Sildenafil treatment for portopulmonary hypertension. Eur Respir J 28: 563-567.
39. Robalino, B.D. and Moodie, D.S. ( 1991) Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 17: 492-498.
40. Rodriguez-Roisin, R., Krowka, M.J., Herve, P. and Fallon, M.B. ( 2004) Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 24: 861-880.
41. Rubin, L.J., Badesch, D.B., Barst, R.J., Galie, N., Black, C.M., Keogh, A. et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903.
42. Schraufnagel, D.E. and Kay, J.M. ( 1996) Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 17: 1-15.
43. Simonneau, G., Galie, N., Rubin, L.J., Langleben, D., Seeger, W., Domenighetti, G. et al. (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43: 5S-12S.
44. Tuder, R.M., Cool, C.D., Geraci, M.W., Wang, J., Abman, S.H., Wright, L. et al. (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159: 1925-1932.